A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme.
about
The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug TherapyDrug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeuticsThe status of gene therapy for brain tumorsProdrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy)Dexamethasone inhibits the HSV-tk/ ganciclovir bystander effect in malignant glioma cells.A dual function fusion protein of Herpes simplex virus type 1 thymidine kinase and firefly luciferase for noninvasive in vivo imaging of gene therapy in malignant gliomaAdenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice.Stem cells as cellular vehicles for gene therapy against glioblastomaGene therapy for brain tumors: basic developments and clinical implementationA short perspective on gene therapy: Clinical experience on gene therapy of gliomablastoma multiformeSui generis: gene therapy and delivery systems for the treatment of glioblastomaNovel delivery strategies for glioblastomaPolymeric drug delivery for the treatment of glioblastomaTargeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanomaWhat next for newly diagnosed glioblastoma?Optimizing targeted gene delivery: chemical modification of viral vectors and synthesis of artificial virus vector systemsRetrovolution: HIV-driven evolution of cellular genes and improvement of anticancer drug activationNovel therapeutic approaches for various cancer types using a modified sleeping beauty-based gene delivery systemIntrathecal gene therapy for treatment of leptomeningeal carcinomatosis.Gene therapy of carcinoma using ultrasound-targeted microbubble destructionMolecular and functional imaging technology for the development of efficient treatment strategies for gliomas.Surgical management of high-grade glioma: a standard of care.Human gene therapy and imaging in neurological diseases.Selective delivery of therapeutic agents for the diagnosis and treatment of cancer.Influence of vector design and host cell on the mechanism of recombination and emergence of mutant subpopulations of replicating retroviral vectors.Remission of invasive, cancer stem-like glioblastoma xenografts using lentiviral vector-mediated suicide gene therapy.Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regressionSafety and efficacy of suicide gene therapy with adenosine deaminase 5-fluorocytosine silmutaneously in in vitro cultures of melanoma and retinal cell lines.Neural stem cell therapy for cancer.Biodegradable polymeric nanoparticles show high efficacy and specificity at DNA delivery to human glioblastoma in vitro and in vivoTwo-year survival of low-grade and high-grade glioma patients using data from the Swedish Cancer Registry.A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancerEvolution of malignant glioma treatment: from chemotherapy to vaccines to viruses.Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disordersCancer suicide gene therapy with TK.007: superior killing efficiency and bystander effect.Inhibitory effects of the ultrasound-targeted microbubble destruction-mediated herpes simplex virus-thymidine kinase/ganciclovir system on ovarian cancer in mice.Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene.Experimental approaches for the treatment of malignant gliomas.Optogenetic neuronal stimulation promotes functional recovery after strokeUrokinase-targeted fusion by oncolytic Sendai virus eradicates orthotopic glioblastomas by pronounced synergy with interferon-β gene.
P2860
Q24609522-6B3F902E-732C-417B-AF48-776B5DC8FB0EQ24616751-554EBF78-5B92-49BC-B398-DEF43EA5FCFAQ24651009-26986E0F-9B3B-4682-9EFE-7B8A63B50340Q24792836-A5AE99F3-D309-4ECB-821C-10A5A9F499EEQ24797338-70524E4B-477B-4A9F-B5E1-0962BC02DA30Q24802324-C8075E2C-102A-46DB-929D-58A1525C92CBQ24815069-06EAD3F7-E6C1-4B4D-AAB6-CDE2760C0995Q26771835-34B8664B-CB14-46F5-ACDC-A96C4A75EE88Q26829086-8E6D3CAA-01A4-4CFF-9DA6-F22223A6C973Q26849375-EEE8D483-258D-4609-A1BA-2DE18ED07568Q26850467-E030032F-6E60-42F1-B4E7-C4775B5B9A2AQ27006099-124FC47A-83AB-4966-9E24-9C30AA413224Q27010046-078E3588-4EEF-474B-858B-F00628E32D35Q27326700-33A1B3AC-4855-486A-89E1-3A76C1412842Q28086839-EA954C53-8242-4DE9-A647-B1128DD57C7AQ28476268-772EECF8-F8A8-4426-A920-8EAE5780B60AQ28482505-DFC7ADBC-1B0E-45E7-A190-6EF552466EAAQ28660424-63895BF5-B4E6-4BF3-8636-6444C539C7DEQ30425756-A3688C84-C79C-4EBD-B910-CE7BC8EBB6EBQ30434291-956D34F5-9E26-489C-A356-DBCA9771A934Q30775012-F1408F71-8507-4652-8682-7150AA86FB34Q30838365-674D1A5E-C069-4394-B9D1-648795ED21E9Q31023442-CD6BAB2A-CBAE-4BA1-89D8-E298A1BA0E35Q33230098-F6528961-22E3-44C4-9C4C-0603810A2E3EQ33407011-C3F28998-6C24-4457-BD5E-7311D4AA7103Q33484184-E75492EE-8E3B-4B39-BA81-681EE07B5B6EQ33551268-4095D6DF-DBD3-4088-9282-12A0511E02AAQ33556564-FCBCE7F4-7C70-44DE-A168-5408A84D4608Q33704489-91090E41-09AB-45E9-A8CF-48EC581884E1Q33716020-DA6127A2-A23D-4843-9B55-F0EF5F7DCE33Q33772575-3DA492EB-D3C0-421C-915D-3E4D967A11E5Q33786353-300F10A4-C789-4CE4-9904-11690E63BD72Q33923950-DD75708E-CC25-48F0-9517-35EE46E10FB0Q33985663-5B6FE8CA-A30B-4E65-84BE-DA71E24EF8BFQ34027421-9719542C-D718-412C-AE7B-0738BF094178Q34119623-218DB119-1F88-4D60-959D-C434F9992E31Q34124630-E89F9EB0-3A9F-4504-8B68-5746C34C7959Q34127138-AA87E911-ACAF-4D0E-9530-926E2C9B66D2Q34144724-633B442E-BB3C-423C-A974-6ED48CB45E32Q34183374-6D700EFD-24FF-4E1D-AB22-00F8790832A4
P2860
A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
A phase III clinical evaluatio ...... eated glioblastoma multiforme.
@en
A phase III clinical evaluatio ...... eated glioblastoma multiforme.
@nl
type
label
A phase III clinical evaluatio ...... eated glioblastoma multiforme.
@en
A phase III clinical evaluatio ...... eated glioblastoma multiforme.
@nl
prefLabel
A phase III clinical evaluatio ...... eated glioblastoma multiforme.
@en
A phase III clinical evaluatio ...... eated glioblastoma multiforme.
@nl
P1433
P1476
A phase III clinical evaluatio ...... reated glioblastoma multiforme
@en
P2093
P304
P356
10.1089/104303400750038499
P577
2000-11-01T00:00:00Z